# Management of Blunt Cerebrovascular Injuries (BCVI)

### **<span style="font-family: 'Calibri',sans-serif;">Management of Blunt Extra – Cranial Carotid and Vertebral Artery Injury in Adults (BCVI)</span>**

<span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;"> </span>

#### **<span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">PURPOSE: </span>**

<span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">To define guidelines in caring for the trauma patient with diagnosis of blunt extra – cranial carotid and vertebral artery injuries (BCVI) </span>

**<span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;"> </span>**

#### **<span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">GUIDELINE: </span>**

<u><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">Screening (Denver Criteria)</span></u>

<span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">Signs/Symptoms</span>

<span style="font-size: 11.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">Potential arterial hemorrhage from neck/nose/mouth</span>

<span style="font-size: 11.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">Cervical bruit (&lt;50 years old)</span>

<span style="font-size: 11.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">Expanding cervical hematoma</span>

<span style="font-size: 11.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">Focal neurologic defect: TIA, hemiparesis, vertebrobasilar symptoms, Horner’s syndrome</span>

<span style="font-size: 11.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">Neurologic deficit inconsistent with head CT</span>

<span style="font-size: 11.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">Stroke on CT or MRI</span>

<span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;"> </span>

<span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">Risk Factors for BCVI</span>

<span style="font-size: 11.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">High-energy transfer mechanism</span>

<span style="font-size: 11.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">Displaced midface fracture (Lefort II or III)</span>

<span style="font-size: 11.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">Mandible Fracture</span>

<span style="font-size: 11.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">Complex skull fracture/basilar skull fracture/occipital condyle fracture</span>

<span style="font-size: 11.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">Severe TBI with GCS &lt;6</span>

<span style="font-size: 11.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">Cervical spine fracture, subluxation, or ligamentous injury at any level</span>

<span style="font-size: 11.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">Near hanging with anoxic brain injury</span>

<span style="font-size: 11.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">Clothesline type injury or seat belt abrasion with significant swelling, pain, or altered mental status</span>

<span style="font-size: 11.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">TBI with thoracic injuries</span>

<span style="font-size: 11.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">Scalp degloving</span>

<span style="font-size: 11.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">Thoracic vascular injuries</span>

<span style="font-size: 11.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">Blunt cardiac rupture</span>

<span style="font-size: 11.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">Upper rib fracture</span>

<u><span style="font-size: 5.0pt; font-family: 'Calibri',sans-serif;"><span style="text-decoration: none;"> </span></span></u>

<u><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">Screening Modality</span></u>

<span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">High quality CT Angiography of the neck is an acceptable modality. </span>

<span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">Digital subtraction 4-vessel angiography may be required if metallic foreign bodies prevent adequate visualization on CTA </span>

<span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">Duplex Ultrasound is *not* adequate for screening for BCVI. </span>

<span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;"> </span>

<span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">\*\*\* If CTA is ordered to screen for BCVI, a TEG needs to be drawn\*\*\*</span>

<span style="font-size: 5.0pt; font-family: 'Calibri',sans-serif;"> </span>

<span style="text-decoration: underline;"><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">Grading Scale </span></span>

<span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">Grade 1 – Intimal irregularity with &lt; 25% narrowing. </span>

<span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">Grade 2 – Dissection or intramural hematoma with &gt; 25% narrowing </span>

<span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">Grade 3 – Pseudoaneurysm </span>

<span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">Grade 4 – Occlusion </span>

<span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">Grade 5 – Transection with extravasation</span>

<u><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">Treatment </span></u>

<span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">Patients with extracranial carotid and vertebral artery injuries should be treated as outlined below unless: Arterial transection with active hemorrhage is present and/or risk of bleeding from other traumatic injuries prohibits the use of anticoagulation. </span>

<span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;"> </span>

<span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">Recommendation based on injury grade</span>

<span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;"> </span>

<span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">Grade 1 and 2 </span>

<span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">81 mg Aspirin </span>

<span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;"> </span>

<span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">Grade 3</span>

<span style="font-size: 11.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">81 mg Aspirin </span>

<span style="font-size: 11.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">Neurosurgeon and/or Neuro Interventionalist consultation</span>

<span style="font-size: 11.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">Unlikely to resolve spontaneously with antithrombotic therapy alone.<span style="mso-spacerun: yes;"> </span>Close follow-up needed.</span>

<span style="font-size: 11.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">Stenting should be avoided due to increased risk for stent thrombosis.</span>

<span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;"> </span>

<span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">Grade 4</span>

<span style="font-size: 11.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">81 mg Aspirin</span>

<span style="font-size: 11.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">Neurosurgeon and/or Neuro Interventionalist consultation</span>

<span style="font-size: 11.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">Goal to prevent propagation of thrombus</span>

<span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;"> </span>

<span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">Grade 5 </span>

<span style="font-size: 11.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">Neurosurgeon and/or Neuro Interventionalist consultation</span>

<span style="font-size: 11.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">Endovascular intervention depending on clinical picture:</span>

- - - - <span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">Cerebral ischemic events despite the use of anticoagulation or antiplatelet therapy. </span>
            - <span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">Progressing luminal stenosis despite adequate antithrombotic therapy</span>
            - <span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">Clinical or radiographic evidence of cerebral perfusion failure due to inadequate collateral blood flow.</span>
            - <span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">Vertebral artery pseudoaneurysms, as they can rupture into the spinal canal producing epidural and subarachnoid hemorrhage</span>
            - <span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">Carotid pseudoaneurysms do not require *urgent* endovascular therapy, as they pose no </span><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">significant risk of bleeding. </span>

\*\*\*Should results of TEG reveal a hypercoagulable state in the setting of BCVI (MA &gt;63 or angle &gt; 77), strong consideration for early initiation of antithrombotic therapy should be made despite competing risk factors due to increased risk for CVA\*\*\*

<u><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">Monitoring</span></u>

<span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">Repeat CTA at 7-days post injury for injury grades 1-3 to assess for resolution of injury and monitor for any progression of luminal stenosis despite antithrombotic therapy, which may benefit from endovascular intervention</span>

<span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">Continued aspirin for 3 months </span>

<span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">CTA is recommended at 3 months to determine the status of the BCVI and the need for further medical or endovascular therapy.</span>

<div drawio-diagram="16"><img src="https://paths.trauma.ai/uploads/images/drawio/2023-04/drawing-4-1682101263.png" alt=""/></div>

**<span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">APPROVAL: </span>**

<span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">Author: Bennett J. Berning, MD  
</span>

<span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">Reviewer: Division of Acute Care Surgery, University of Nebraska Medical Center</span>

<span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">Approval Date: 1/12/2022</span>

**References:**

1. <span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: +mn-ea; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; color: #212121; mso-font-kerning: 12.0pt;">Cogbill TH, Moore EE, Meissner M, et al. The spectrum of blunt injury to the carotid artery: a multicenter perspective. *J Trauma*. 1994;37(3):473-479. doi:10.1097/00005373-199409000-00024</span>
2. <span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: +mn-ea; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; color: #212121; mso-font-kerning: 12.0pt;">Biffl WL, Moore EE, Ryu RK, et al. The unrecognized epidemic of blunt carotid arterial injuries: early diagnosis improves neurologic outcome. *Ann Surg*. 1998;228(4):462-470. doi:10.1097/00000658-199810000-00003</span>
3. <span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: +mn-ea; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; color: #212121; mso-font-kerning: 12.0pt;">Mutze S, Rademacher G, Matthes G, Hosten N, Stengel D. Blunt cerebrovascular injury in patients with blunt multiple trauma: diagnostic accuracy of duplex Doppler US and early CT angiography. *Radiology*. 2005;237(3):884-892. doi:10.1148/radiol.2373042189</span>
4. <span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: +mn-ea; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; color: #212121; mso-font-kerning: 12.0pt;">Miller PR, Fabian TC, Croce MA, et al. Prospective screening for blunt cerebrovascular injuries: analysis of diagnostic modalities and outcomes. *Ann Surg*. 2002;236(3):386-395. doi:10.1097/01.SLA.0000027174.01008.</span>
5. <span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: +mn-ea; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; color: #212121; mso-font-kerning: 12.0pt;">Burlew CC, Sumislawski JJ, Behnfield CD, et al. Time to stroke: A Western Trauma Association multicenter study of blunt cerebrovascular injuries. *J Trauma Acute Care Surg*. 2018;85(5):858-866. doi:10.1097/TA.0000000000001989</span>
6. <span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: +mn-ea; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; color: #212121; mso-font-kerning: 12.0pt;">Biffl WL, Moore EE, Offner PJ, Brega KE, Franciose RJ, Burch JM. Blunt carotid arterial injuries: implications of a new grading scale. *J Trauma*. 1999;47(5):845-853. doi:10.1097/00005373-199911000-00004</span>
7. <span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: +mn-ea; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; color: #212121; mso-font-kerning: 12.0pt;">Russo RM, Davidson AJ, Alam HB, et al. Blunt cerebrovascular injuries: Outcomes from the American Association for the Surgery of Trauma PROspective Observational Vascular Injury Treatment (PROOVIT) multicenter registry. *J Trauma Acute Care Surg*. 2021;90(6):987-995. doi:10.1097/TA.0000000000003127</span>
8. <span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: +mn-ea; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; color: #212121; mso-font-kerning: 12.0pt;">Bromberg WJ, Collier BC, Diebel LN, et al. Blunt cerebrovascular injury practice management guidelines: the Eastern Association for the Surgery of Trauma. *J Trauma*. 2010;68(2):471-477. doi:10.1097/TA.0b013e3181cb43da</span>
9. <span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: +mn-ea; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; color: #212121; mso-font-kerning: 12.0pt;">Kim DY, Biffl W, Bokhari F, et al. Evaluation and management of blunt cerebrovascular injury: A practice management guideline from the Eastern Association for the Surgery of Trauma \[published correction appears in J Trauma Acute Care Surg. 2020 Aug;89(2):420\]. *J Trauma Acute Care Surg*. 2020;88(6):875-887. doi:10.1097/TA.0000000000002668</span>
10. <span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: +mn-ea; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; color: #212121; mso-font-kerning: 12.0pt;">Biffl WL, Moore EE, Offner PJ, et al. Optimizing screening for blunt cerebrovascular injuries. *Am J Surg*. 1999;178(6):517-522. doi:10.1016/s0002-9610(99)00245-7</span>
11. <span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; color: #212121; background: white;">Sumislawski JJ, Moore HB, Moore EE, Swope ML, Pieracci FM, Fox CJ, Campion EM, Lawless RA, Platnick KB, Sauaia A, Cohen MJ, Burlew CC. Not all in your head (and neck): Stroke after blunt cerebrovascular injury is associated with systemic hypercoagulability. J Trauma Acute Care Surg. 2019 Nov;87(5):1082-1087. doi: 10.1097/TA.0000000000002443. PMID: 31453984.</span>